Perfluorocarbons Therapeutics in Modern Cancer Nanotechnology for Hypoxia-induced Anti-tumor Therapy

Simple item page
dc.catalogadorjca
dc.contributor.authorSatija, Saurabh
dc.contributor.authorSharma, Prabal
dc.contributor.authorKaur, Harpreet
dc.contributor.authorDhanjal, Daljeet S.
dc.contributor.authorChopra, Reena S.
dc.contributor.authorKhurana, Navneet
dc.contributor.authorVyas, Manish
dc.contributor.authorSharma, Neha
dc.contributor.authorTambuwala, Murtaza M.
dc.contributor.authorBakshi, Hamid A.
dc.contributor.authorCharbe, Nitin B.
dc.contributor.authorZacconi, Flavia C. M.
dc.contributor.authorChellappan, Dinesh K.
dc.contributor.authorDua, Kamal
dc.contributor.authorMehta, Meenu
dc.date.accessioned2023-08-25T20:29:48Z
dc.date.available2023-08-25T20:29:48Z
dc.date.issued2021
dc.description.abstractWith an estimated failure rate of about 90%, immunotherapies that are intended for the treatment of solid tumors have caused an anomalous rise in the mortality rate over the past decades. It is apparent that resistance towards such therapies primarily occurs due to elevated levels of HIF-1 (Hypoxia-induced factor) in tumor cells, which are caused by disrupted microcirculation and diffusion mechanisms. With the advent of nanotechnology, several innovative advances were brought to the fore; and, one such promising direction is the use of perfluorocarbon nanoparticles in the management of solid tumors. Perfluorocarbon nanoparticles enhance the response of hypoxia-based agents (HBAs) within the tumor cells and have been found to augment the entry of HBAs into the tumor micro-environment. The heightened penetration of HBAs causes chronic hypoxia, thus aiding in the process of cell quiescence. In addition, this technology has also been applied in photodynamic therapy, where oxygen self-enriched photosensitizers loaded perfluorocarbon nanoparticles are employed. The resulting processes initiate a cascade, depleting tumour oxygen and turning it into a reactive oxygen species eventually to destroy the tumour cell. This review elaborates on the multiple applications of nanotechnology based perfluorocarbon formulations that are being currently employed in the treatment of tumour hypoxia.
dc.description.funderRebecca L. Cooper Medical Research Foundation
dc.description.funderSydney Partnership for Health, Education, Research and Enterprise (SPHERE)
dc.fechaingreso.objetodigital2023-08-25
dc.format.extent12 páginas
dc.fuente.origenWOS
dc.identifier.doi10.2174/1381612827666210830100907
dc.identifier.eissn1873-4286
dc.identifier.issn1381-6128
dc.identifier.pubmedidMEDLINE:34459378
dc.identifier.urihttps://doi.org/10.2174/1381612827666210830100907
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/74506
dc.identifier.wosidWOS:000711147200002
dc.information.autorucEscuela de Química; Zacconi, Flavia C. M. ; 0000-0002-3676-0453; 1011127
dc.issue.numero43
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final4387
dc.pagina.inicio4376
dc.revistaCurrent Pharmaceutical Design
dc.rightsacceso restringido
dc.subjectTumour hypoxia
dc.subjectNanotechnology
dc.subjectPerfluorocarbons
dc.subjectHBA
dc.subjectHIF-1
dc.subjectCancer
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePerfluorocarbons Therapeutics in Modern Cancer Nanotechnology for Hypoxia-induced Anti-tumor Therapy
dc.typereseña
dc.volumen27
sipa.codpersvinculados1011127
sipa.indexWoS
sipa.trazabilidadWOS;18-03-2022
sipa.trazabilidadORCID;2023-08-21
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Perfluorocarbons Therapeutics .pdf
Size:
72.69 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas